ASTRAZENECA COMPLETES US LICENSING AGREEMENT WITH IRONWOOD PHARMACEUTICALS FOR LESINURAD
AstraZeneca today announced that it has completed the licensing agreement with Ironwood Pharmaceuticals for the exclusive US rights to Zurampic (lesinurad) and the fixed-dose combination of lesinurad and allopurinol. Zurampic is approved in the US, in combination with a xanthine oxidase inhibitor, for the treatment of hyperuricemia associated with uncontrolled gout. The fixed-dose combination will be submitted for regulatory review in the second half of 2016.
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology - as well as in infection and neuroscience. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
CONTACTS
Media Enquiries |
|
|
Neil Burrows |
UK/Global |
+44 7824 350541 |
Vanessa Rhodes |
UK/Global |
+44 7880 400690 |
Karen Birmingham |
UK/Global |
+44 7818 524012 |
Jacob Lund |
Sweden |
+46 8 553 260 20 |
Michele Meixell |
US |
+1 302 885 2677 |
Investor Enquiries |
|
|
UK |
|
|
Thomas Kudsk Larsen |
|
+44 7818 524185 |
Nick Stone |
RIA |
+44 7717 618834 |
Henry Wheeler |
Oncology |
+44 7788 354619 |
Craig Marks |
Finance |
+44 7881 615764 |
Christer Gruvris |
ING |
+44 7827 836825 |
US |
|
|
Lindsey Trickett |
CVMD |
+1 240 543 7970 |
Mitchell Chan |
Oncology |
+1 240 477 3771 |
Dial / Toll-Free |
|
+1 866 381 7277 |
Key: RIA - Respiratory, Inflammation and Autoimmunity, CVMD - Cardiovascular and Metabolic Disease, ING - Infection, Neuroscience and Gastrointestinal
3 June 2016
-ENDS-
